229 related articles for article (PubMed ID: 34927013)
21. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.
He Y; Zhao Y; Wang L; Bohrer LR; Pan Y; Wang L; Huang H
Oncogene; 2018 Jan; 37(4):534-543. PubMed ID: 28991226
[TBL] [Abstract][Full Text] [Related]
22. Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase.
Tortorici M; Borrello MT; Tardugno M; Chiarelli LR; Pilotto S; Ciossani G; Vellore NA; Bailey SG; Cowan J; O'Connell M; Crabb SJ; Packham G; Mai A; Baron R; Ganesan A; Mattevi A
ACS Chem Biol; 2013 Aug; 8(8):1677-82. PubMed ID: 23721412
[TBL] [Abstract][Full Text] [Related]
23. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1.
Lin Y; Wu Y; Li J; Dong C; Ye X; Chi YI; Evers BM; Zhou BP
EMBO J; 2010 Jun; 29(11):1803-16. PubMed ID: 20389281
[TBL] [Abstract][Full Text] [Related]
24. Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione.
Bailey CP; Figueroa M; Gangadharan A; Lee DA; Chandra J
Front Immunol; 2020; 11():2196. PubMed ID: 33042135
[TBL] [Abstract][Full Text] [Related]
25. LSD1/CoREST is an allosteric nanoscale clamp regulated by H3-histone-tail molecular recognition.
Baron R; Vellore NA
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12509-14. PubMed ID: 22802671
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of Crosstalk between the LSD1 Demethylase and HDAC1 Deacetylase in the CoREST Complex.
Song Y; Dagil L; Fairall L; Robertson N; Wu M; Ragan TJ; Savva CG; Saleh A; Morone N; Kunze MBA; Jamieson AG; Cole PA; Hansen DF; Schwabe JWR
Cell Rep; 2020 Feb; 30(8):2699-2711.e8. PubMed ID: 32101746
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation of neuronal Lysine-Specific Demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2.
Toffolo E; Rusconi F; Paganini L; Tortorici M; Pilotto S; Heise C; Verpelli C; Tedeschi G; Maffioli E; Sala C; Mattevi A; Battaglioli E
J Neurochem; 2014 Mar; 128(5):603-16. PubMed ID: 24111946
[TBL] [Abstract][Full Text] [Related]
28. Expanding the druggable space of the LSD1/CoREST epigenetic target: new potential binding regions for drug-like molecules, peptides, protein partners, and chromatin.
Robertson JC; Hurley NC; Tortorici M; Ciossani G; Borrello MT; Vellore NA; Ganesan A; Mattevi A; Baron R
PLoS Comput Biol; 2013; 9(7):e1003158. PubMed ID: 23874194
[TBL] [Abstract][Full Text] [Related]
29. Thermodynamic characterization of the binding interaction between the histone demethylase LSD1/KDM1 and CoREST.
Hwang S; Schmitt AA; Luteran AE; Toone EJ; McCafferty DG
Biochemistry; 2011 Feb; 50(4):546-57. PubMed ID: 21142040
[TBL] [Abstract][Full Text] [Related]
30. Extranucleosomal DNA enhances the activity of the LSD1/CoREST histone demethylase complex.
Kim SA; Chatterjee N; Jennings MJ; Bartholomew B; Tan S
Nucleic Acids Res; 2015 May; 43(10):4868-80. PubMed ID: 25916846
[TBL] [Abstract][Full Text] [Related]
31. Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia.
van Bergen MGJM; van der Reijden BA
Front Oncol; 2019; 9():1027. PubMed ID: 31649884
[TBL] [Abstract][Full Text] [Related]
32. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
34. Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1).
Sakane N; Kwon HS; Pagans S; Kaehlcke K; Mizusawa Y; Kamada M; Lassen KG; Chan J; Greene WC; Schnoelzer M; Ott M
PLoS Pathog; 2011 Aug; 7(8):e1002184. PubMed ID: 21876670
[TBL] [Abstract][Full Text] [Related]
35. Molecular mimicry and ligand recognition in binding and catalysis by the histone demethylase LSD1-CoREST complex.
Baron R; Binda C; Tortorici M; McCammon JA; Mattevi A
Structure; 2011 Feb; 19(2):212-20. PubMed ID: 21300290
[TBL] [Abstract][Full Text] [Related]
36. Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.
Zhu Q; Liu C; Ge Z; Fang X; Zhang X; Strååt K; Björkholm M; Xu D
PLoS One; 2008 Jan; 3(1):e1446. PubMed ID: 18197256
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors.
Wang S; Li ZR; Suo FZ; Yuan XH; Yu B; Liu HM
Eur J Med Chem; 2019 Apr; 167():388-401. PubMed ID: 30780087
[TBL] [Abstract][Full Text] [Related]
38. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
39. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
[TBL] [Abstract][Full Text] [Related]
40. Regulation of LSD1 histone demethylase activity by its associated factors.
Shi YJ; Matson C; Lan F; Iwase S; Baba T; Shi Y
Mol Cell; 2005 Sep; 19(6):857-64. PubMed ID: 16140033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
